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Abstract
In this manuscript, we discuss the development and clinical use of a thermoplastic modular
microsystem for the high-throughput analysis of CTCs directly from whole blood. The modular
system offers some innovative features that address challenges currently associated with many
CTC platforms; it can exhaustively process 7.5 ml of blood in less than 45 min with recoveries
>90%. In addition, the system automates the post-selection CTC processing steps and thus,
significantly reduces assay turnaround time (from selection to enumeration <1.5 h as compared to
>8 h for many reported CTC platforms). The system is comprised of 3 functional modules
including; (i) a thermoplastic CTC selection module composed of high aspect ratio (30 μm × 150
μm) channels containing anti-EpCAM antibodies that is scalable in terms of throughput by
employing channel numbers ranging from 50 to 320 – the channel number is user selected to
accommodate the volume of blood that must be processed; (ii) an impedance sensor module for
label-less CTC counting; and (iii) a staining and imaging module for the placement of released
cells into a 2D array within a common imaging plane for phenotypic identification. To
demonstrate the utility of this system, blood samples from patients with local resectable and
metastatic pancreatic ductal adenocarcinoma (PDAC) were analyzed. We demonstrate the ability
to select EpCAM positive CTCs from PDAC patients in high purity (>86%) and with excellent
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yields (mean = 53 CTCs per ml for metastatic PDAC patients) using our modular system. In
addition, we demonstrate the ability to detect CTCs in PDAC patients with local resectable disease
(mean = 11 CTCs per ml).
Introduction
The presence of circulating tumor cells (CTCs) in cancer patients was documented as early
as 1869.1 CTCs are shed from many solid tumors and have been implicated as key
participants in the metastatic process. As such, CTCs have attracted attention as a new class
of biomarkers that can provide valuable clinical information for staging of patients, early
diagnosis of relapse, guiding therapy, monitoring response to particular therapies and
detection of disease recurrence.2–21 Another attribute of CTCs is that they can easily be
obtained through a simple blood draw, potentially obviating the need for securing biopsies.
The main challenge associated with the analysis of CTCs is their low frequency; 1–100
CTCs per ml of blood. Thus, highly sensitive and specific enrichment techniques are
required to enable effective CTC analysis. Three important metrics are considered when
evaluating CTC enrichment techniques; (i) throughput, defined as the maximum sample
processing rate (volume flow rate in ml/h); (ii) recovery, an indicator of the number of target
cells selected from the input sample; and (iii) purity defined as the ratio of CTCs selected to
the total number of cells enriched.
CellSearch™ (Veridex) is the only FDA-approved technology for CTC enrichment and
utilizes functionalized magnetic beads that target tumor specific antigens associated with
CTCs, which in most cases is the epithelial cell adhesion molecule, EpCAM. This system
has been validated through many clinical reports, however, it suffers from low purity (0.01 –
0.1%) and poor clinical sensitivity.22–23 Thus, new technologies that can provide higher
CTC sensitivity and specificity as well as automate the entire processing pipeline are
needed.
Microfluidics has been demonstrated to be viable platforms for CTC analyses,24–30 and offer
several compelling operational characteristics: (i) They can be configured to select CTCs
based on several different selection modalities.31 (ii) Microfluidic chips operate in a closed
architecture, minimizing the potential of sample contamination. (iii) Microfluidic devices
can be produced in a high production mode and at low-cost using, for example,
thermoplastics and micro-replication.28, 32–33 (iv) CTC selection devices can be integrated
to other processing steps to fully automate sample processing.
Microfluidic devices using affinity selection typically demonstrate higher purities compared
to size-based selection, but at the expense of throughput.28–29, 32–34 CTC microfluidic
affinity beds have employed a variety of geometrical configurations and fluid dynamics to
optimize recoveries.28–29, 32–33 Low throughput typically results from the necessity of using
relatively low linear velocities to promote highly efficient antigen/antibody
interactions.28–29 For example, a CTC chip utilizing a staggered arrangement of microposts
produced a recovery of 65% with a throughput of 1 ml/h.29 Other geometries have employed
herringbone channels to induce chaotic mixing leading to recoveries on the order of 91%
and purities from 9% to 14%.35 Recently, a nanotextured herringbone device consisting of
silicon nanopillars was reported.36 A flow rate of 1 ml/h was used for CTC selection from
clinical samples. Adams and coworkers utilized high aspect ratio sinusoidal channels to
reduce pressure drops and increased throughput (1.6 ml/h) with a recovery of ~97%.
Irrespective of the CTC selection modality employed, the enumeration process, which
consists of staining the selected cells with DAPI, anti-CD45 antibodies and a cytokeratin
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cocktail, has been difficult and tedious to undertake requiring imaging of large areas and, in
some cases, several imaging planes. For example, using a positive selection CTC
microfluidic device developed by our group,28 6 h of imaging time was required to
enumerate the cells. As another example, Stott et al. reported a total scan time of 8 h for a
CTC microfluidic chip.35
Another challenge for CTC assays is that some epithelial cancers do not show high
sensitivity to the CTC assay, for example pancreatic cancer. Pancreatic ductal
adenocarcinoma, PDAC, is one of the deadliest forms of pancreatic cancer and the fourth-
leading cause of cancer-related deaths worldwide. According to the National Cancer
Institute, it is one of the most prognostically unfavorable human cancers with the rate of
incidence nearly equal to the rate of mortality.37–40 Unfortunately, several CTC technologies
provide low clinical yields for this disease. For example, the CellSearch system
demonstrated clinical CTC yields for metastatic PDAC patients in the range of 0–1 per 7.5
ml of blood.41–42 Recently, a micro-pillar-based CTC fluidic device has generated fairly
high yields of CTCs for PDAC patients using anti-EpCAM antibodies as the selection
marker.29
Herein we present a novel system for the selection and subsequent analysis of CTCs directly
from blood samples using a modular design approach to achieve high throughput, high
recovery, high purity and full process automation with a short assay turnaround time. The
three main components of the modular system included: (i) A high throughput (HT) CTC
selection module used for the affinity enrichment of CTCs; (ii) an impedance sensor module
for label-free counting; and (iii) a staining and imaging module for placing the CTCs in a
small viewing area. The HT-CTC selection module consisted of a novel architecture with a
parallel network of high aspect ratio curvilinear channels arranged in a z-configuration. This
module could be scaled from 50 to 320 microchannels depending on the blood volume
processing needs. As a prescreening tool, we included into the system an impedance sensor
module that utilized Pt electrodes to count cells released from the selection module. The
third module, referred to as the staining and imaging module, was used for collection,
staining, and visualization of the selected cells for phenotype identification. This module
eliminated the arduous task of scanning large area selection beds by placing CTCs within a
small viewing area and a single imaging plane. The clinical utility of this modular
microsystem was tested using blood samples from patients with local resectable and
metastatic PDAC.
Experimental Section
Fabrication of microfluidic modules
The CTC processing system (see Figure 1) consisted of three separate, task-specific polymer
modules: (1) HT-CTC selection module; (2) impedance sensing module; and (3) the staining
and imaging module. Hot embossing and laser ablation were used as the primary tools for
fabrication of the polymer fluidic modules as described previously (see Electronic
Supplementary Information, ESI, for details).43
The HT-CTC module (see Figure 2) was made from the thermoplastic, cyclic olefin
copolymer, COC. This module consisted of an array of high-aspect ratio sinusoidal
microchannels with a nominal width of 30 μm and depth of 150 μm serving as the CTC
selection bed. Selection beds were addressed using a single inlet and outlet channel arranged
in a z-configuration. Selection channel numbers were user selectable and ranged from 50 –
320.
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After hot embossing, the HT-CTC module and cover plate were flood exposed to broad band
UV light at ~22 mW/cm2 (254 nm) for 15 min using a low pressure Hg lamp (GLF-42,
Jelight Company Inc., Irvine, CA). UV exposure produced carboxylic acid surfaces that
were used for the covalent attachment of monoclonal anti-EpCAM antibodies for CTC
selection.44–45 Following UV exposure, the substrate was enclosed with a cover plate by
thermal fusion bonding at a temperature of 132°C and a bonding pressure of ~1 N/cm2.
After assembly, the surface of the microfluidic channels was modified using EDC-NHS
chemistry. This consisted of 50 mg/ml EDC (1-Ethyl-3-[3-dimethylaminopropyl]
carbodiimide hydrochloride), 5 mg/ml NHS (N-hydroxysuccinimide) in 100 mM MES (pH
6), followed by incubation with a solution of anti-EpCAM monoclonal antibodies (0.5 mg/
ml; 150 mM PBS buffer, pH 7.4). The optimum concentration of the antibody was chosen
based on studies to optimize CTC recovery (Figure S1 in the ESI).
For the fabrication and operation of the impedance sensing module, readers should refer to
the ESI. Also provided in the ESI is the information on the processing electronics and data
collection and analysis.
The design of the staining and imaging module, which was made from PMMA, is presented
in Figure 3. It consisted of two independent microchannel networks, one consisting of an
array of smaller microchannels laser machined (6 × 8 μm2) into the module cover plate and
a second set of fluidic channels (50 μm depth; varying width) embossed into the substrate,
which consisted of interleaving channels. Both parts were thermal fusion bonded at 106°C
and a pressure of ~3 N/cm2 with the patterned surfaces facing each other. The staining and
imaging module possessed 800 pores arranged in a 2D matrix spaced by 100 μm.
Connection between modules was accomplished using glass capillaries (Polymicro
Technologies, Phoenix, AZ; id = 150 μm) compression fit to inlet and outlet ports of each
module (see Figure S4C in the ESI). Capillaries were connected to each other using low
dead volume interconnects secured from Polymicro.
Materials
Pt wires (75 μm diameter), which were used as the impedance microelectrodes, were
purchased from Sigma-Aldrich (St. Louis, MO). COC (Topas 6013S-04) plates (1/8″ thick)
and films (250 μm thick) were acquired from Topas Advanced Polymers, Florence KY. 1/8″
thick PMMA hot embossing stock was acquired from SABIC Polymershapes (Raleigh, NC).
250 μm thick PMMA films used as the imaging module cover plates were purchased from
Goodfellow (Oakdale, PA). PEEK tubing and connectors were purchased from IDEX Health
& Science (Oak Harbor, WA). Chemicals used for PMMA and COC surface cleaning and
modification included reagent grade isopropyl alcohol, EDC, NHS, fetal bovine serum, and
MES all of which were acquired from Sigma-Aldrich. Monoclonal anti-EpCAM antibody
was obtained from R&D Systems (Minneapolis, MN). Tris-glycine buffer was obtained
from Bio-Rad Laboratories (Hercules, CA). PBS buffer and trypsin were purchased from
Sigma-Aldrich. For CTC immunostaining, the nuclear stain DAPI was obtained from
Thermo Pierce Technologies (Rockford, IL). Anti-CD45-FITC antibody (HI30 clone) and
anti-cytokeratin antibodies (8/19 conjugated to Texas Red) were purchased from
eBiosciences (San Diego, CA). Bovine serum albumin (BSA) in PBS buffer (pH 7.4) was
secured from Sigma.
Cell culture and patient samples
For a description of culturing the model cell lines used for these studies, please see the ESI.
Also contained in the ESI is information on the accrual of patient samples used in these
studies.
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Blood specimens were collected into BD Vacutainer® tubes containing EDTA as
anticoagulant (Becton-Dickinson, Franklin Lakes, NJ) and following homogenization, 3 ml
of patient blood was transferred into a disposable Luer Lok™ syringe (BD Biosciences).
Immediately after transfer, blood samples were processed through the HT-CTC selection
module. A PHD2000 syringe pump (Harvard Apparatus, Holliston, MA) was used to drive
the blood through the HT-CTC selection module at the appropriate volume flow rate.28 The
HT-CTC selection bed was then flushed with 2.5 ml of PBS at a linear velocity of 4 mm/s to
remove any nonspecifically bound cells.
Operation of the integrated system and data collection and analysis
Following CTC selection and bed washing, 200 μl of the CTC release buffer consisting of
0.25% w/v trypsin in 25 mM TRIS/192 mM glycine buffer (pH 7.4) was infused through the
HT-CTC selection module to allow for the release of CTCs from the selection channels. The
concentration of trypsin selected here was based upon similar conditions used for
trypsinizing cells in culture and thus, minimize damage to membrane proteins used for
characterization (i.e., immunostaining). Also, trypsinizing cells does affect viability, but it
does not induce cell lysing (data not shown) making the cells available for impedance
sensing and staining. Upon release, the CTCs traversed through the impedance sensor and an
electrical signal was recorded using in-house designed electronics.28 Impedance responses
generated from CTCs were counted when the signal-to-noise ratio exceeded 3:1. Cells
counted were directed into the staining and imaging module for staining with fluorescently
labeled markers.
The stained cells were imaged using an inverted Olympus 1×71 microscope (Center Valley,
PA) equipped with a high resolution (1344 × 1024) CCD camera (Hamamatsu ORCA-03G)
and a mercury arc lamp. Images were collected using 40x (0.6 NA) and 60x (0.7 NA) dry
lens objectives and analyzed using Metamorph software (Olympus). Exposure times for the
DAPI, FITC/CD45, and Texas Red/CK channels were 50 ms, 600 ms and 600 ms,
respectively. See the ESI for the staining procedure of the cells. Statistical analysis was
performed using the Kruskal-Wallis Test (p=0.05) for three sample groups of healthy
donors, local resectable patients and metastatic PDAC patients. For pair wise test analysis,
Wilcoxon Rank-Sum (p=0.05) was applied.
Results and Discussion
HT-CTC selection module
The HT-CTC module utilized COC as the substrate material. COC demonstrates higher UV
transmissivity compared to PMMA, therefore generating a higher surface density of
carboxylic acid groups on high aspect ratio channel walls. These surface-confined carboxyl
groups serve as functional scaffolds for the attachment of CTC recognition elements.45–46
Higher UV transmission also resulted in a more uniform modification of the high-aspect
ratio microchannel walls when made from COC. COC also demonstrated higher CTC
purities compared to PMMA.46
Considering the requirements for the microfluidic channel geometry and linear velocity of
the sample through the selection channels to maximize recovery,28 it was clear that higher
throughput could be achieved by either increasing the number of parallel microchannels or
increasing the depth of the microchannels without changing the width. For results reported
herein, we used larger number of parallel channels as a method for increasing throughput.
For example, the previously reported device used 51 parallel channels (cross-section 30 μm
× 150 μm) and could process 1 ml of whole blood in 37 min. Thus, it would take nearly 4.7
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h for this device to process 7.5 ml. By increasing the number of channels to 320, 7.5 ml
input volumes could be processed in <45 min using an average linear velocity of 2 mm/s.
To address all parallel channels within the selection bed employing large numbers of parallel
sinusoidal channels, we adopted a unique z-configuration (Figure 2). In this configuration,
fluid enters the selection bed through a single inlet channel with a larger cross-sectional area
and exits through a single outlet channel also possessing a larger cross-section compared to
the sinusoidally-shaped selection channels (see ESI). Both inlet and outlet channels were
perpendicular to the high aspect ratio selection channels (Figure 2A).
The z-configuration also provided the smallest possible footprint for addressing the isolation
bed and allows for easy scaling of the CTC selection bed. For example, in a recently
proposed fluidic design for neutrophil isolation,47 bifurcation was used for addressing
parallel channels of the isolation bed, which nearly doubled the footprint of the device to
allocate sufficient space for the fluid distribution network. Furthermore, compared to our
previously reported design,28 the high linear fluid velocities in the inlet and outlet channels
of the z-configuration allowed for more efficient removal of persistent air bubbles that were
inevitably introduced into the device during operation, which may compromise recovery.
Uniformity of the fluid flow using the z-configuration is highly dependent on the flow
resistance ratio between the inlet/outlet channels and the flow resistance in the parallel
channels. In general, wider (lower fluidic resistance) inlet channels and longer and/or
narrower (higher fluidic resistance) parallel channels show higher flow uniformity
throughout the array. Inhomogeneity of the fluid flow rate is exacerbated by the number of
parallel channels in the array. As seen in Figure 4A, a parabolic fill profile was observed
over the entire selection bed during filling. Qualitatively, if each channel of the array was
filling under a constant linear velocity, the filling profile of the array should show a linear
gradient.
To evaluate flow uniformity in the CTC selection bed with various numbers of sinusoidal
channels and for various lengths of the selection bed, we performed numerical simulations
to establish average linear velocities of fluid in individual sinusoidal microchannels. Due to
the numerical limits of simulating large geometries using computational fluid dynamics
(CFD), we employed a method described by Zhang and coworkers.48 This method splits the
selection bed into an interconnected system of individually defined parallel channels and the
addressing inlet/outlet channels. Each channel segment was treated as a fluidic resistor, and
the flow dynamics through the entire system was described by pressure and mass balance
equations.48
Figure 4B presents solutions for microfluidic selection beds with 50, 250 and 320 channels
possessing dimensions of 0.03 × 0.15 × 30 mm3 along with the results for 320 channels with
varying lengths of 30, 20 and 8.4 mm. As can be seen from this data, for the 320 channel
device with 8.4 mm selection channel lengths, the maximum and minimum flow velocities
fall outside the range of 1 mm/s – 4 mm/s, a range that was determined to provide CTC
recoveries >80%.28 However, when using 320 channels and incorporating a length of 30
mm, the average flow velocity remains within an acceptable range for maximum CTC
recovery.
The simulated results were also confirmed experimentally (Figure 4C). The results indicated
good agreement with the simulation results; the slowest flow rates were observed in the
middle and fastest at the outer channels with an RSD of 16%. We also evaluated the
distribution of selected MCF-7 cells inside a HT-CTC bed modified with anti-EpCAM
antibodies. MCF-7 cells (~500) labeled with a PKH 67 fluorescent membrane dye were
spiked into normal blood and processed using the selection bed comprised of 320 channels
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and the numbers of MCF-7 cells per channel were counted using a fluorescence microscope.
Figure 4D shows the selected cell distribution within individual channels. A uniform
distribution of cells across the entire series of microchannels occurred with most of the
channels capturing 1 or 2 cells and only a few capturing 3 – 4 cells or no cells at all. The
overall average CTC recovery for these experiments was 83.1% ±5.2% (n = 4). Selection
beds with at least 30 mm channel lengths were necessary to achieve recoveries >90%
(Figure S2 in the ESI).
Impedance sensor module
The impedance sensor adopted a geometry similar to that reported previously by our
group.28 Using this sensor, we were interested in determining the ability to discriminate
between leukocytes and CTCs based on size differences, which is the cell characteristic
measured at the operating frequency (40 kHz). At this operating frequency, a
misclassification rate of 15% was noted (see ESI, Figure S3), which was similar to results
provided by optical imaging (Figure S3B, ESI). The impedance sensor in its current format
can measure signatures from single cells that are unlabeled and thus, can serve as a
prescreening tool for assessing the need to immunocytochemically stain for CTCs (see ESI).
Staining and imaging module
PMMA was selected as the substrate of choice for the staining and imaging module due to
the high quality machining it generated using laser ablation as well as its favorable optical
properties.49
The design and operation of this novel 2D imaging module are shown in Figure 3. It
consisted of two independent networks of channels, an interleaving input/output channel
network interconnected using an array of smaller channels positioned orthogonally to the
input/output channels. The interconnecting/feed channel interface generated a pore structure,
whose dimensions were determined by the size of the interconnecting channel (8 μm base
and 6 μm height). During operation, CTCs released from the primary selection bed were
transported through the impedance sensor to the staining and imaging module where they
were retained due to their larger size as compared to the size of the pore. After collection at
each pore, CTCs could be fixed, permeabilized, and immunostained directly within the
staining and imaging module followed by fluorescence imaging. The unique geometry of the
staining and imaging module offered important benefits: (i) A small footprint (0.16 cm2) as
compared to the primary selection bed (4 cm2 for the 50-channel z-configuration module),
which significantly reduced the time required for imaging; (ii) cells are brought to a single
focal plane further reducing imaging time; and (iii) the highly ordered configuration of the
pores allowed for indexing cell position, which also reduced imaging time.
To validate the performance of the staining and imaging module, we determined the
collection efficiency of fixed and unfixed cells at a flow rate that was used to move the
released CTCs from the selection channels to the staining and imaging module. We used
Hs578ST cells seeded into PBS as a model for these studies. The collection efficiency was
defined as the ratio of cells collected at the pores to the number of cells counted by the
impedance sensor (see Figure S4, ESI). We determined that for fixed cells, the collection
efficiency of the staining and imaging module was 96 ±6% (n=5) while for unfixed cells, the
collection efficiency was 85 ±11% (n=5). The difference in the collection efficiency is
indicative of the higher deformability of unfixed cells compared to those that are fixed (see
Figure S5, ESI).50
We also found that the cells resident within a pore adhered to the pore structure even when
the solution flow was terminated. Therefore, the cells could be trapped at the pore without
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requiring boundary conditions to contain the cells. Because of this adhesion, we could
remove the staining and imaging module from the system and place it on a conventional
microscope stage without losing cells from their respective pore location.
We next evaluated the collection efficiency of the staining and imaging module for patient
samples (n = 4, PDAC, see ESI). For the PDAC samples analyzed, the collection efficiency
of CTCs by the staining and imaging module was 72 ±13% (see Figure S4, ESI). While the
staining and imaging module demonstrated higher collection efficiencies for the Hs578T cell
line compared to the clinical samples, this difference could have arisen from impedance
signals recorded for leukocytes as well as the CTCs, which were not present in the cell line
studies. Also, most of the CTCs are in an apoptotic state and therefore, their cell membrane
may not be rigid enough to withstand the pressure exerted on the cell by the pore structure
(see Figure S5, ESI).51–53
CTCs in metastatic and local resectable PDAC patients
For metastatic PDAC patient blood samples, we isolated an average of 53 ±29 CTCs/ml,
median = 51/ml with a range of 9 to 95 CTCs/ml. To establish assay reproducibility, we also
processed three aliquots from the same patient sample. An RSD value of 14% (n=3) was
obtained. CTCs were selected in all patients with metastatic PDAC. For the healthy blood
donors, in most cases no CTCs were detected.
We also analyzed blood from patients who had been determined to have local resectable
PDAC by CT scans. We found an average of 11 CTCs/ml for this group of patients. Based
on the Kruskal-Wallis test (p = 0.002), there was a significant difference in the CTCs/ml
between metastatic patients, local resectable patients, and healthy donors. Pairwise
Wilcoxon Rank-Sum tests suggested that there was a significant difference between
metastatic patients and healthy donors (p= 0.005). Between local resectable PDAC patients
and healthy donors, there was also a statistically significant difference in terms of CTC
numbers (p=0.011). Comparison between metastatic and local resectable patients also
indicated a significant CTC number difference (p=0.023). These results remained significant
when accounting for multiple testing using the Hochberg method (p-values of 0.016, 0.022,
and 0.023). This data is summarized in Figure 5A.
The presence of CTCs from local resectable patients may be indicative of micrometastasis,
which is undetectable by conventional diagnostic methods. CT scans, which are commonly
used for tumor imaging, are less informative with regard to the micrometastatic nature of the
tumor because they cannot detect tumors smaller than 1 cm and thus, may not be effective
for assessing the micrometastatic nature of PDAC.37 Continuous monitoring of CTC counts
from this group of patients may be important in predicting the disease recurrence after
surgical resection.
The purity of the assay was determined as well. The purity was calculated using the ratio of
the number of CTCs selected to the total number of cells selected and was found to be 86
±12% for all samples analyzed (see ESI for further discussion of purity and Table S1). The
high purity levels observed in our studies were mainly due to the relatively high shear forces
applied to the selected cells during the post selection wash.46 While the CTCs selected on
the channel walls remained unaffected by the high shear forces due to the high KD value (3
× 10−9 M) between EpCAM and anti-EpCAM antibodies and the multi-point contact,28 the
non-specifically adsorbed leukocytes are more easily removed from the surface due to their
apparent lower adhesion force to the surface.
We noticed microclusters of CTCs in 71% of the PDAC blood samples (Figure 5Ci–l).
These clusters were predominantly found near the entrance to the sinusoidal microchannels
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of the HT-CTC selection module. Recent reports on CTC isolation have cited the presence
of similar clusters. It is speculated that these clusters form in circulation or break off from
the primary tumor as a cohort of cells.6, 54
We also noted the presence of DAPI(+) cells that stained positive for both cytokeratins and
CD45. The frequency of these “double positive” cells was on the order of 1.6 ±2 cells/ml,
which was lower than the CTC and/or leukocyte occurrence (see Table S1). This is contrary
to other reports, which indicated a much higher frequency of such cells.35 Although at this
point we do not understand the origin of these cells, they could be a sub-population of CTCs
acquiring mesenchymal markers or leukocytes with an abnormally increased cytokeratin
expression. In the current studies, these cells were not classified as CTCs, however, they
were included in purity calculations as contaminating cells.
Conclusion
In this study we adopted a modular approach with 3 task-specific modules for processing
CTCs in an automated fashion. The first module consisted of a HT-CTC selection module
designed with a z-configuration that was scalable to allow processing of input volumes from
1 ml to 7.5 ml in <45 min. The selected cells could be released from the antibody-decorated
selection surface and shuttled through an impedance sensor module. The inclusion of the
impedance sensor module was useful as a prescreening tool to allow the user to make
decisions based on the impedance response as to whether staining and imaging of selected
CTC fractions was necessary, which can result in a significant reduction in assay cost and
time.
We also described a unique staining and imaging module consisting of a high density array
of pore structures made at the intersection of large input/output channels and smaller
interconnecting channels. This module demonstrated a significant reduction in the analysis
time for CTC imaging; 6 h processing time for analyzing cells in the selection module to 10
min when using the staining and imaging module. Although the collection efficiencies were
slightly lower for CTCs generated from clinical samples compared to cell lines, this can be
rectified by re-engineering the pore structures to possess smaller dimensions and at the same
time increasing the number of pores.
Using this system, we have achieved some interesting clinical data for PDAC as well, both
local resectable and metastatic PDAC. We have detected CTCs in all patients diagnosed
with PDAC (see Table S1) and with high purity resulting from the high shear forces exerted
on the cells following selection in the HT-CTC module. This high purity level should
provide the ability to secure high quality molecular profiles of the CTCs that can be used to
guide therapy by stratifying patients with PDAC and other solid tumors.
Using our integrated and modular system, CTC assay time was significantly reduced
compared to the approach requiring manual processing. For the manual case, the assay time
was found to be ~8 h (CTC selection, staining and imaging) with the majority of time
relegated to imaging the relatively large selection bed. For the microsystem presented in this
manuscript, the assay time was reduced to 1.5 h (45 min CTC selection time even for 7.5 ml
of blood, 15 min release time, 20 min fixation, permeabilization and staining time and 10
min imaging time).
The modular approach presented herein provides multiple advantages toward constructing
integrated fluidic systems for CTC analysis. These include: (i) Flexibility in the selection of
materials used for construction of task-specific modules to optimize performance for each
processing step; (ii) ease of reconfiguration of fluidic modules without re-engineering the
entire system to accommodate alternative processing steps; (iii) the ability to use separate
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fabrication modalities optimized for each module; and (iv) high production yields of
integrated systems. The main challenge when using a modular design approach is the proper
interconnections between modules. Improper nterconnections can produce dead volumes,
which can potentially result in CTC loss during processing. While interconnecting modules
using capillaries as done here can produce some dead volumes and are somewhat
cumbersome to assemble, our current efforts are directed toward integrating the modular
system using interconnects that minimize unswept volumes and are easily manufactured and
assembled.55
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Modular microfluidic system for CTC analysis. (A) Schematic representation of the
operation of the system and the three modules comprising the system including the HT-CTC
module, the impedance sensing module and the staining and imaging module. Arrows
indicate flow of sample (1 and 1′), wash buffer (2 and 2′), CTC release buffer (3 and 3′), and
fixation and staining reagents (4 and 4′). For detailed operational procedures please refer to
the Experimental section. (B) Picture of the assembled system. Roman numerals correspond
to modules described in (A). (C) Micrographs and data plots showing various outputs of the
three modules including: (I) HT-CTC selection module for the positive selection of CTCs;
(II) electrical signatures of CTCs obtained using the impedance sensor module; and (III)
images of CTCs stained with DAPI and collected at the staining and imaging module.
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(A) Schematic operation of the HT-CTC module with 50 parallel, sinusoidal microchannels
and inlet/outlet channels arranged in the z-configuration. The large arrow indicates sample
flow direction through the selection channels. (B) SEM of the selection bed showing high-
aspect ratio sinusoidal microchannels and the output channel (top). (C) SEM of one of the
high-aspect ratio sinusoidal channels. (D) SEM image of a portion of the high-precision
micromilled brass molding tool showing the sample inlet port with continuously changing
width and height for minimizing unswept volumes during sample (i.e., blood) introduction.
(E) Assembled HT-CTC modules with different numbers of microfluidic sinusoidal
channels designed for efficient processing of various sample volumes.
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Staining and imaging module. (A) Assembly process; (a) – cover plate with an array of 8 × 6
μm2 channels, which form pores for retaining cells between the interleaving inlet and outlet
channels (b). (B) Schematic of an assembled module and its operation; Red – input
channels; Blue – output channels; Yellow – interconnecting channels. (C) Image of the
staining and imaging module filled with fluorescein. The lower fluorescence intensity in the
interconnecting channels is due to the smaller cross-sectional area of these channels
compared to the input/output channels. (D) Fluorescence image of CTCs retained by pores.
The cells were stained with DAPI for visualization. (E) High magnification fluorescence
image of Hs578T cells retained at the pore structures of the staining and imaging module.
These cells were stained with PKH67 lipid membrane green fluorescent dye for
visualization.
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(A) Various stages of filling a 320-channel HT-CTC module (20 mm length) with a dye
solution. (B) Numerical simulation results showing the distribution of flow velocities for
different configurations of the CTC selection beds arranged in a z-configuration. (C)
Average linear velocity of fluid in 16 groups of 20 adjacent sinusoidal high aspect ratio
microchannels based on the results depicted in Figure 4A (filled bars) and theoretical values
obtained via numerical simulation (empty bars). (D) Distribution of MCF-7 cells selected in
20 mm long microchannels.
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Selection and enumeration of CTCs via immunophenotyping. (A) Box plot from CTCs
isolated from 7 metastatic PDAC patients, 5 healthy donors and 5 local resectable PDAC
patients. (B) Fluorescence images of various selected cells from a metastatic PDAC patient:
(i) CTC; (ii) two white blood cells; and (iii) cluster of CTCs. (b, f, j) CTC marker for
Cytokeratin 8/19 (red) with b, j positive for this marker and f negative for this marker; and
(c, g, k) leukocyte antigen marker CD45 (green) with c, k negative for this marker and g
positive for this marker. Micrographs (i–l) are of an aggregate of 6 CTCs captured in the
HT-CTC module. This aggregate showed positive for cytokeratins 8/19 (j) and negative for
leukocyte marker CD45 (k). Bars are 10 μm.
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